Articles tagged with Radiation Therapy
Research presented at the ASTRO Annual Meeting has shown that short-term hormone therapy added to radiation increases survival for medium-risk prostate cancer patients, while a shorter radiation course is effective in reducing recurrence rates. Additionally, proton therapy reduces recurrences and is well-tolerated in prostate cancer pa...
Combining chemotherapy with radiotherapy more than doubles event-free survival for patients with locally advanced head and neck cancer without prior surgery. Non-platinum-based chemotherapy shows long-term benefit with lower toxicity compared to platinum therapies.
The world's largest congress on ion therapy brought together leading experts to discuss the latest scientific and clinical developments in radiation therapy. The meeting marked a significant milestone in the technology and clinical application of ion radiation, with over 70,000 patients worldwide treated so far.
The American Society for Radiation Oncology (ASTRO) is partnering with Gilda's Club Chicago to promote cancer survivorship. The two organizations will participate in the Survivor Circle exhibit at ASTRO's 51st Annual Meeting, highlighting programs that help patients and families cope with cancer.
Halos of Hope, a non-profit organization established in 2007, will partner with ASTRO to provide comfort and dignity to chemo patients. The partnership aims to educate members about the organization's mission and programs focused on supporting cancer survivors.
A large study by Mayo Clinic researchers found that patients treated with radiotherapy after prostate cancer surgery experienced very few complications, contradicting concerns about toxicity and side effects. The study suggests that radiation treatment is an effective and safe option for patients with recurrent cancer.
Researchers have identified highly radiosensitive patients who can guide personalized radiotherapy, avoiding severe side effects. The study aims to develop a blood test that can predict patient reaction to radiotherapy, enabling tailored treatment and improved tumour control.
A study found that patients who had surgery before radiation treatment are more likely to complete therapy, while those with other illnesses or chemotherapy are less likely. This highlights the importance of addressing comorbidities and toxic effects of treatment in radiation therapy.
Researchers found that inhibiting NF-kappa B reduced radiation toxicity in zebrafish embryos, offering a potential therapeutic strategy for cancer patients receiving radiation therapy. The study also suggests that downmodulating NF-kappa B activity may be more beneficial than completely ablating it to protect against radiation effects.
Men with coronary artery disease-induced congestive heart failure or heart attack who receive hormone therapy before or along with radiation therapy for prostate cancer have a higher risk of death, according to a study. However, in men without comorbidities, hormone therapy was not associated with an increased risk of all-cause mortality.
Researchers found a strong link between radiotherapy treatment and fatigue, with increases in serum markers of cytokine activity also associated. This study suggests that exposure to radiation releases inflammatory cytokines contributing to fatigue.
Patients who received radiotherapy for low-grade glioma brain tumors showed significant cognitive decline compared to those who did not receive treatment. The study found that attentional functioning, executive functioning, and information processing speed were lower in patients given radiotherapy. Deferring treatment or using modern r...
The American Society for Radiation Oncology has named its 12th class of ASTRO Fellows, recognizing individuals who have made significant contributions to the field of radiation oncology through research, patient care, education, or leadership. The fellows will be recognized at the 51st Annual Meeting in November.
A new trial shows that chemotherapy plus radiotherapy, either with or without surgery, are viable options for patients with stage IIIA (N2) non-small-cell lung cancer. The treatment improved overall survival and progression-free survival rates compared to standard concurrent chemotherapy and radiotherapy alone.
Patients treated for Hodgkin lymphoma with radiation therapy have a substantially higher risk of stroke. After a median follow-up of almost 18 years, 96 patients developed cerebrovascular disease, with the incidence rate for stroke being 2.2 times that in the general population. Risk factors include radiation to the neck and mediastinum.
Researchers have developed a new radiotherapy technique that uses real-time images to guide the radiation beam, allowing for more accurate targeting of tumors. This approach promises to reduce damage to healthy tissue and minimize nasty side effects.
A new study from Henry Ford Hospital found that radical prostatectomy significantly increases long-term survival for men under 50 with prostate cancer. The procedure improved cancer-specific and overall survival rates compared to radiotherapy or watchful waiting, making it the recommended treatment option for younger patients.
Researchers are exploring new treatments for lung cancer using targeted therapies and personalized care. Studies have shown promising results in improving patient outcomes, including the use of molecular targeted therapies and chemotherapy combinations.
A new study reveals that lithium promotes DNA repair in irradiated mice, protecting nerves in the hippocampus by decreasing double-strand DNA breaks. Targeted therapies to enhance DNA repair may provide an avenue for future therapeutic development.
Research at the University of Navarra Hospital found that high-dosage perioperative brachytherapy effectively controls 86% of head and neck tumor cases after a seven-year follow-up. The technique reduces treatment time by two weeks compared to conventional radiotherapy, improving patient outcomes.
The EORTC-NCIC trial found that adding chemotherapy to radiotherapy significantly increases survival in glioblastoma patients, with improved outcomes seen across all clinical prognostic subgroups. The study suggests testing tumour MGMT gene methylation status to identify patients most likely to benefit from this treatment.
A short course of radiation therapy followed by high-quality surgery is the most effective treatment for patients with operable rectal cancer. Recent trials have shown a reduction in local recurrence with radiotherapy and chemotherapy before or after surgery.
A new study finds aggressive surgery followed by targeted radiotherapy is effective in treating a rare form of childhood brain cancer. The treatment improved event-free survival rates, with children under 3 years old showing excellent outcomes.
Researchers investigate thalidomide for biochemical recurrence and adjuvant radiotherapy for improved survival, reducing metastases risk by 29%. Both treatment options show promise for patients with biochemically recurrent prostate cancer after surgery.
Researchers found that fractionated radiation induced an immune imbalance, characterized by elevated expression of pro-inflammatory cytokines, in the distal colonic mucosa. This imbalance persisted even after the end of radiotherapy, with a Th2 profile dominating the immune response.
In a phase III trial, combining endocrine treatment with radiotherapy reduced prostate cancer mortality by half compared to endocrine treatment alone. The study found significant superiority of the combined treatment over hormone therapy alone in reducing prostate cancer-specific mortality and overall survival.
Two studies published in The Lancet show that removing pelvic lymph nodes or external beam radiotherapy does not improve survival rates for women with early endometrial cancer. Removal of lymph nodes increased risk of death by 16%, while radiotherapy showed no benefit in terms of overall survival.
Patients with low-grade gliomas who underwent aggressive surgeries were free of tumor recurrence an average of 15 years after diagnosis. Radiation therapy significantly extended their survival time, with patients living up to six years without tumor recurrence.
A new study presents a promising alternative to traditional treatments for women with breast implants who develop early-stage cancer. Brachytherapy, a targeted radiation treatment, offers better cosmetic outcomes and avoids the risk of implant hardening compared to whole-breast radiation therapy.
The study found that CAPHOSOL results in a low incidence of oral mucositis, moderate to severe pain, and dysphagia. Patient satisfaction rates were high, with 79% describing themselves as satisfied or very satisfied with the treatment.
A study found that patients with locally advanced lung cancer who received proton therapy and chemotherapy had fewer instances of bone marrow toxicity compared to those receiving IMRT and chemotherapy. This suggests that proton therapy may be a more effective option for treating this serious side effect, enabling doctors to give higher...
A large cohort study found that hormone therapy before radiation seed implants for prostate cancer increases the risk of death by 20% in men over 70 years old with early-stage cancer. This treatment approach may have negative effects on survival, particularly for older patients.
A short one-week course of radiation before surgery significantly reduces rectal cancer recurrence risk by 76% compared to post-operative treatment. However, this approach also causes impairment in sexual and bowel functions, affecting the quality of life for patients.
A new type of accelerated partial breast irradiation (APBI) called balloon brachytherapy is as effective in keeping breast cancer from coming back as standard external beam radiation. This shorter treatment option makes radiation therapy more convenient for patients, potentially increasing the rate of breast conservation.
A randomized study found that adding radiation therapy to hormone treatment reduces the risk of dying from prostate cancer by 50% compared to hormone therapy alone. The quality of life at four years after treatment was similar between the two groups, with decreased social function in patients who received combined treatment.
A study presented at the American Society for Therapeutic Radiology and Oncology's 50th Annual Meeting found that proton therapy decreases the risk of patients developing a secondary cancer. Proton therapy is a more targeted form of external beam radiation, which delivers less radiation to bordering normal structures.
Patients who underwent both stereotactic radiosurgery and whole brain radiation experienced a 49% decline in learning and memory functioning, compared to 23% for those who received radiosurgery alone. Neurocognitive function was measured by recall of a list of 12 words after three attempts.
A randomized study found that accelerated hypofractionated whole breast irradiation is as effective as standard five-week treatment in reducing local recurrence and side effects. The new therapy reduces the radiation time to three weeks, resulting in a cost savings of two-thirds compared to traditional treatment.
Multidisciplinary approaches combining chemotherapy, radiotherapy, and surgery have shown promise in treating various cancers, including lung and head and neck cancers. The addition of targeted therapies like pazopanib and cetuximab has demonstrated significant activity in reducing tumor size and improving patient outcomes.
A phase II trial involving 45 patients found that an alternating regimen of chemotherapy and radiotherapy, plus cetuximab, yields favorable complete response rates and long-term results comparable to the best reported in literature. However, skin toxicity and toxicities resulting in patient deaths were also observed.
The American Society for Radiation Oncology has named 30 individuals as its 2008 Fellows, honoring their significant contributions to radiation oncology. The recipients have demonstrated excellence in research, patient care, education, and leadership, making them outstanding professionals in the field.
Researchers at the University of Chicago Medical Center found that targeted radiation therapy can eradicate all signs of disease in up to 21% of patients with stage-IV cancer who have only a few sites of metastasis. The treatment was well-tolerated, with limited side effects, and showed promising results in controlling tumor growth.
Medical physicists are developing new imaging technologies to improve breast cancer detection and treatment. Researchers have also identified ways to predict treatment success using oxygen levels within tumors, and are exploring innovative techniques such as modulated electron therapy for shallow tumor treatment.
A study showed that Caphosol use led to lower OM rates and severity, as well as low pain medication use and high patient satisfaction among cancer patients. High efficacy ratings were also reported by physicians.
A study of 635 men found that radiation therapy significantly prolongs survival in those with recurrent prostate cancer, particularly those with rapidly growing tumors. This breakthrough suggests that radiation can be a life-extending treatment option for these patients.
A study found that radiation treatment after radical prostatectomy was associated with a significant increase in prostate cancer-specific and overall survival. Men with rapid PSA doubling time or high Gleason score benefited from early salvage radiotherapy, which improved survival by over 75%.
A study found that specialist nurse-led clinics provided longer, more frequent consultations and better symptom management for cancer patients undergoing radiotherapy. Patients reported improved social eating, social contact, and reduced oral and nutritional problems. The study suggests that clinical nurse specialists can effectively m...
The American Society for Radiation Oncology (ASTRO) has selected Christopher Rose, M.D., and Joel Tepper, M.D., as the recipients of the 2008 Gold Medal. The award recognizes their outstanding contributions to radiation oncology and leadership in the field.
A study found that Black and Hispanic women are less likely than white women to receive follow-up radiation for early breast cancer, suggesting thousands may be undertreated. The disparity is attributed to various barriers, including logistical problems, insurance status, and patient preferences.
Researchers reviewing randomized trials found that antioxidant supplementation may reduce overall survival in patients receiving radiotherapy. Conversely, no clear evidence suggests that antioxidant treatment increases tumor response rates during chemotherapy.
A new study published in Radiology found that MRI detection of extracapsular extension is an important factor in determining outcome for men scheduled to undergo radiation therapy. Patients with substantial extracapsular spread are more likely to experience recurrence and spread of their cancers.
A study found that 46% of patients received a maximum dose above 10% beyond the prescribed level, while 63% got a minimum dose below 10%, highlighting the need for standardization in intensity-modulated radiation therapy.
Researchers at Henry Ford Hospital are conducting a phase III clinical trial to determine the effectiveness of gene therapy in combination with radiation therapy for patients with intermediate risk prostate cancer. The trial aims to improve patient outcomes by delaying hormone therapy, which can have severe side effects.
Researchers found that a short course of hormonal therapy before and with radiation therapy slowed cancer growth by up to eight years, particularly the development of bone metastases. This delayed cancer progression increased survival rates among older men with potentially aggressive prostate cancer.
The study analyzed data from a national cancer registry and found that type of treatment, sex, race, and insurance status are significantly associated with survival rates among patients with advanced laryngeal cancer. Total laryngectomy was found to be the most effective treatment in increasing survival likelihood.
The overuse of CT scans in the US may result in a future public health problem, with an estimated 1.5-2% of cancers potentially caused by radiation from CT scans. Columbia researchers suggest reducing CT-related radiation dose, replacing scans with non-radiation options, and decreasing total scans to prevent unnecessary irradiation.
Researchers found that simultaneous treatment resulted in a five-year survival rate of 15.1 percent, compared to 10.6 percent with sequential therapy. The study's findings suggest that concurrent chemotherapy and radiation is the new standard of care for locally advanced non-small cell lung cancer.
Scientists at Washington University School of Medicine have identified an enzyme called MOF that is essential for tumor development and growth. By manipulating MOF in tumor cells, researchers hope to make them more sensitive to radiation therapy, which could lead to improved cancer treatment outcomes.
A study of over 11,000 men found that those receiving radiation seed implants had a significant reduction in mortality risk compared to those on watchful waiting/active surveillance within six months of diagnosis. Brachytherapy was shown to be as effective as radical prostatectomy and surgery in extending life expectancy.
A large-scale analysis of over 2,000 patients reveals that men with high-risk prostate cancer who receive radiation therapy after a prostatectomy are less likely to experience disease recurrence. Additionally, men whose cancer persists after surgery benefit from reduced cancer spread if they receive salvage therapy.